EQS-News: aap informs about the invitation to the Annual General Meeting on January 15, 2025
|
EQS-News: aap Implantate AG
/ Key word(s): AGM/EGM
aap Implantate AG ("aap" or "Company") informs about the invitation to the Annual General Meeting published today, which will take place on January 15, 2025 in presence at the Company's headquarters in Berlin. In particular, the Management Board and Supervisory Board will present the annual financial statements, which have now been adopted, the approved consolidated financial statements and the combined management report for the individual and consolidated financial statements for the 2023 financial year to the Annual General Meeting and will also propose a resolution on the discharge of the Management Board and Supervisory Board for the 2023 financial year. In addition, the Supervisory Board will propose the election of a new auditor for the 2024 financial year, as already communicated in the Company's announcement dated December 3, 2023. The Supervisory Board and its Audit Committee expressly welcome the decision of the previous auditor not to carry out the audit of the annual and consolidated financial statements for the 2024 financial year and the opportunity to work with a new auditor in the event of an election. Finally, the Management Board and Supervisory Board will present the audited remuneration report prepared for the 2023 financial year to the Annual General Meeting for discussion. The Annual General Meeting with the presentation of the adopted annual financial statements for 2023 will result in a uniform dividend entitlement for all shares currently issued. As a result, the Company will be able to apply for all previously unlisted shares to be admitted to trading on the regulated market under ISIN: DE000A3H2101. The Company expects this to further increase the liquidity of the Company's listed shares. Further details and the complete agenda of the Annual General Meeting can be found in the invitation and in the documents published on the aap website (www.aap.de). ---------------------------------------------------------------- aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges - About aap Implantate AG aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both through distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.
Forward-looking statements This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments. If you have any questions, please contact: Phone: +49 (0)30 75019 - 141; Fax: +49 (0)30 75019 - 290; Email: r.digirolamo@aap.de
09.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 019-0 |
| Fax: | +49 (0) 30 75 019-111 |
| E-mail: | info@aap.de |
| Internet: | www.aap.de |
| ISIN: | DE000A3H2101 |
| WKN: | A3H210 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2046347 |
| End of News | EQS News Service |
|
|
2046347 09.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | ||
| Sales1 | 11,74 | 9,33 | 12,17 | 11,52 | 11,48 | 12,20 | 0,00 | |
| EBITDA1,2 | -5,14 | -4,77 | -0,77 | -1,71 | -3,67 | 0,16 | 0,00 | |
| EBITDA-Margin3 | -43,78 | -51,13 | -6,33 | -14,84 | -31,97 | 1,31 | 0,00 | |
| EBIT1,4 | -19,77 | -7,89 | -2,61 | -3,39 | -5,19 | -1,60 | 0,00 | |
| EBIT-Margin5 | -168,40 | -84,57 | -21,45 | -29,43 | -45,21 | -13,12 | 0,00 | |
| Net Profit (Loss)1 | -19,52 | -8,79 | -2,52 | -2,56 | -5,13 | -1,85 | 0,00 | |
| Net-Margin6 | -166,27 | -94,21 | -20,71 | -22,22 | -44,69 | -15,16 | 0,00 | |
| Cashflow1,7 | -5,77 | -3,68 | -2,47 | -1,89 | -2,99 | 0,00 | 0,00 | |
| Earnings per share8 | -6,10 | -2,79 | -0,51 | -0,39 | -0,58 | -0,17 | -0,18 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| aap Implantate | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3H210 | DE000A3H2101 | AG | 17,35 Mio € | 10.05.1999 | 9F4MF94Q+7M | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 0,00 | 0,00 | 0,00 | -0,85 | 1,60 | -5,80 | 1,52 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.01.2025 | - | 14.08.2024 | - | 23.08.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -15,82% | +15,75% | +30,71% | +97,62% | -98,34% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
